Elicio Therapeutics, Inc. (ELTX) stock
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.50−0.06 (-3.85%)
Close on Nov 13, 2026Market cap $39.42MP/E –Yield –
Elicio Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Elicio Therapeutics's gross margin for the twelve months ending Dec 31, 2021 was 98.5%. For fiscal 2022 it was 100.0%, against 98.5% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 100.0% | +1.5 |
| FY2021 | Dec 31, 2021 | 98.5% | +39.8 |
| FY2020 | Dec 31, 2020 | 58.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | 98.3% | +25.8 |
| Q3 FY2021 | Sep 30, 2021 | 100.0% | +42.1 |
| Q2 FY2021 | Jun 30, 2021 | 100.0% | +45.7 |
| Q1 FY2021 | Mar 31, 2021 | 100.0% | +44.3 |
| Q4 FY2020 | Dec 31, 2020 | 72.5% | – |
| Q3 FY2020 | Sep 30, 2020 | 57.9% | – |
| Q2 FY2020 | Jun 30, 2020 | 54.3% | – |
| Q1 FY2020 | Mar 31, 2020 | 55.7% | – |
See a number that looks wrong?